Search Result

Results for "

intravascular

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Biochemical Assay Reagents (7) CDK (1) Complement System (4) Cyclin G-associated Kinase (GAK) (1) Drug Derivative (1) Drug Metabolite (1) Elastase (5) Environmental Pollutants (1) Factor Xa (3) Interleukin Related (1) Isotope-Labeled Compounds (1) Kallikrein (1) MMP (1) NF-κB (1) PI3K (1) Proteasome (2) Reference Standards (6) SARS-CoV (5) Ser/Thr Protease (1) TNF Receptor (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (9) Endocrinology (2) Inflammation/Immunology (5) Metabolic Disease (1)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Inhibitory Antibodies

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17443

Sivelestat Maximum Cited Publications 30 Publications Verification EI546; LY544349; ONO5046	Elastase SARS-CoV	Cancer
Sivelestat (EI546) is a competitive inhibitor of human neutrophil elastase, with an IC₅₀ of 44 nM and a K_i of 200 nM. Sivelestat (EI546) has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19 .

HY-B0385

Gabexate mesylate 4 Publications Verification FOY	Proteasome Factor Xa	Inflammation/Immunology
Gabexate mesylate (FOY) is is a competitive and non-antigenic synthetic inhibitor of trypsin-like serine proteinases. Gabexate mesylate inhibits human thrombin, urokinase, plasmin, and Factor Xa with K_is of 0.97, 1.3, 1.6, and 8.5 μM, respectively. Gabexate mesylate binds to human and bovine tryptase with K_is of 3.4 nM and 18 μM, respectively. Gabexate mesylate exerts an anticoagulant effect on the clotting activity of thrombin and has anti-inflammatory effect by viainhibition of NF-κB, proinflammatory cytokines, and nitric oxide. Gabexate mesylate is used for pancreatitis and disseminated intravascular coagulation .

HY-17443A

Sivelestat sodium Maximum Cited Publications 30 Publications Verification ONO5046-Na; Sodium sivelestat; EI546 sodium; LY544349 sodium	Elastase SARS-CoV	Cancer
Sivelestat (EI546) sodium is a competitive inhibitor of human neutrophil elastase, with an IC₅₀ of 44 nM and a K_i of 200 nM. Sivelestat (EI546) sodium has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19 .

HY-147297

Pelecopan BCX9930	Complement System	Inflammation/Immunology
Pelecopan (BCX9930) is a potent, selective, orally active inhibitor of complement factor D with an IC₅₀ value of 14.3 nM. Pelecopan can target factor D to prevent both intravascular and extravascular hemolysis in PNH. Pelecopan also be used for other alternative pathway (AP) mediated diseases .

HY-W145519

Hydroxyethyl starch (MW170-230 kDa)	Environmental Pollutants Biochemical Assay Reagents	Cardiovascular Disease
Hydroxyethyl starch (MW170-230 kDa) is a type of hydroxyethyl starch with a molecular weight of 170-230 kDa. A medium-molecular-weight hydroxyethyl starch (HES 200/0.62) exhibits minimal intravascular hydrolysis. The rapidly degradable medium-molecular-weight Hydroxyethyl starch 200/0.5 causes almost no coagulation disorders and improves hemorheological parameters .

HY-17443B

Sivelestat sodium tetrahydrate Maximum Cited Publications 30 Publications Verification EI546 sodium tetrahydrate; LY544349 sodium tetrahydrate; ONO5046 sodium tetrahydrate	Elastase SARS-CoV	Cancer
Sivelestat (EI546) sodium tetrahydrate is a competitive inhibitor of human neutrophil elastase, with an IC₅₀ of 44 nM and a K_i of 200 nM. Sivelestat (EI546) sodium tetrahydrate has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19 .

HY-P990952

Zaltenibart OMS906	Ser/Thr Protease Complement System	Metabolic Disease Inflammation/Immunology
Zaltenibart (OMS906) is an IgG4 humanized monoclonal antibody and MASP-3 inhibitor. By inhibiting MASP-3, Zaltenibart achieves upstream inhibition of the alternative complement pathway. MASP-3 is an upstream activator of Factor D (Factor D), a key enzyme in the alternative complement pathway. Zaltenibart prevents both intravascular hemolysis and extravascular hemolysis. Zaltenibart is applicable to research related to paroxysmal nocturnal hemoglobinuria .

HY-B1362

Iopromide 2 Publications Verification	Biochemical Assay Reagents	Cardiovascular Disease
Iopromide is a non-ionic, monomeric, iodine-based contrast medium for intravascular administration.

HY-142121

Iopentol	Biochemical Assay Reagents	Others
Iopentol is a non-ionic, intravascular contrast media .

HY-109513

Ioxilan 1 Publications Verification	Biochemical Assay Reagents	Others
Ioxilan is a low-osmolar, nonionic and tri-iodinated diagnostic contrast agent. Ioxilan is also an X-ray contrast agent for excretory urography and contrast enhanced computed tomographic (CECT) imaging of the head and body. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs .

HY-17443R

Sivelestat (Standard) EI546 (Standard); LY544349 (Standard); ONO5046 (Standard)	Elastase SARS-CoV Reference Standards	Cancer
Sivelestat (Standard) is the analytical standard of Sivelestat. This product is intended for research and analytical applications. Sivelestat (EI546) is a competitive inhibitor of human neutrophil elastase, with an IC50 of 44 nM and a Ki of 200 nM. Sivelestat (EI546) has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19 .

HY-19101

ONO-3307	Kallikrein	Cardiovascular Disease
ONO-3307 is a protease inhibitor that competitively inhibits a variety of proteases including trypsin, thrombin, plasma kallikrein, plasmin, pancreatic kallikrein, and chymotrypsin. ONO-3307 alleviates endotoxin-induced experimental disseminated intravascular coagulation (DIC) in rats. ONO-3307 can be used in the study of thrombosis and protease-mediated diseases .

HY-17443BR

Sivelestat sodium tetrahydrate (Standard) EI546 sodium tetrahydrate (Standard); LY544349 sodium tetrahydrate (Standard); ONO5046 sodium tetrahydrate (Standard)	Reference Standards Elastase SARS-CoV	Cancer
Sivelestat (sodium tetrahydrate) (Standard) is the analytical standard of Sivelestat (sodium tetrahydrate). This product is intended for research and analytical applications. Sivelestat (EI546) sodium tetrahydrate is a competitive inhibitor of human neutrophil elastase, with an IC₅₀ of 44 nM and a K_i of 200 nM. Sivelestat (EI546) sodium tetrahydrate has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19 .

HY-172316

BAY 3389934	Factor Xa	Cardiovascular Disease
BAY 3389934 is a selective dual inhibitor of factor IIa and factor Xa, with an IC₅₀ of 4.9 nM for factor IIa and an IC₅₀ of 0.66 nM for factor Xa. BAY 3389934 directly inhibits the activities of factor IIa and factor Xa and regulates the common coagulation pathway. BAY 3389934 exhibits anticoagulant and organ-protective effects. BAY 3389934 can be used in the research of sepsis and coagulopathy .

HY-B1362S

Iopromide-d3	Isotope-Labeled Compounds	Cardiovascular Disease
Iopromide-d₃ is the deuterium labeled Iopromide. Iopromide is a non-ionic, monomeric, iodine-based contrast medium for intravascular administration.

HY-B0385R

Gabexate mesylate (Standard) FOY (Standard)	Reference Standards Proteasome Factor Xa	Inflammation/Immunology
Gabexate (mesylate) (Standard) is the analytical standard of Gabexate (mesylate). This product is intended for research and analytical applications. Gabexate mesylate (FOY) is is a competitive and non-antigenic synthetic inhibitor of trypsin-like serine proteinases. Gabexate mesylate inhibits human thrombin, urokinase, plasmin, and Factor Xa with Kis of 0.97, 1.3, 1.6, and 8.5 μM, respectively. Gabexate mesylate binds to human and bovine tryptase with Kis of 3.4 nM and 18 μM, respectively. Gabexate mesylate exerts an anticoagulant effect on the clotting activity of thrombin and has anti-inflammatory effect by viainhibition of NF-κB, proinflammatory cytokines, and nitric oxide. Gabexate mesylate is used for pancreatitis and disseminated intravascular coagulation .

HY-B1362R

Iopromide (Standard)	Biochemical Assay Reagents Reference Standards	Cardiovascular Disease
Iopromide (Standard) is the analytical standard of Iopromide. This product is intended for research and analytical applications. Iopromide is a non-ionic, monomeric, iodine-based contrast medium for intravascular administration.

HY-116462

ONO-EI-601	Drug Metabolite	Others
ONO-EI-601 is the major metabolite of human neutrophil elastase inhibitor ONO-5046. ONO-5046 has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19 .

HY-109513R

Ioxilan (Standard)	Biochemical Assay Reagents Reference Standards	Others
Ioxilan (Standard) is the analytical standard of Ioxilan. This product is intended for research and analytical applications. Ioxilan is a low-osmolar, nonionic and tri-iodinated diagnostic contrast agent. Ioxilan is also an X-ray contrast agent for excretory urography and contrast enhanced computed tomographic (CECT) imaging of the head and body. Intravascular injection results in opacification of vessels in the path of flow of the contrast medium, permitting radiographic visualization of the internal structures of the human body until significant hemodilution occurs .

HY-142121R

Iopentol (Standard)	Biochemical Assay Reagents Reference Standards	Others
Iopentol (Standard) is the analytical standard of Iopentol. This product is intended for research and analytical applications. Iopentol is a non-ionic, intravascular contrast media .

HY-105363

RGH-1962	Others	Cardiovascular Disease
RGH-1962 is an orally active antithrombotic agent. RGH-1962 prevents endotoxin-induced decreases in fibrinogen level and platelet count, reduces the level of fibrin degradation products and inhibits the endotoxin-induced enhancement of fibrinolytic activity in a rabbit model of endotoxin-induced disseminated intravascular coagulation. RGH-1962 can be used for the study of thrombotic diseases .

HY-105364

RGH-1875 hydriodide GYKI 39521 hydriodide	Others	Cardiovascular Disease
RGH-1875 (GYKI 39521) hydriodide is the hydriodide of RGH-1875. RGH-1875 is an orally active antithrombotic agent. RGH-1875 prevents endotoxin-induced decreases in fibrinogen level and platelet count, reduces the level of fibrin degradation products and inhibits the endotoxin-induced enhancement of fibrinolytic activity in a rabbit model of endotoxin-induced disseminated intravascular coagulation. RGH-1875 can be used for the study of thrombotic diseases .

HY-P991022

Ruxoprubart NM8074	Complement System	Endocrinology
Ruxoprubart (NM8074) is an inhibitor of complement factor B (Bb subunit). Ruxoprubart selectively binds to active Bb to inhibit the alternative complement pathway without affecting the classical complement pathway. By blocking the activities of AP C3 and C5 convertases, Ruxoprubart effectively inhibits red blood cell hemolysis and reduces C3b deposition, thereby preventing intravascular and extravascular hemolysis. Ruxoprubart can be used in research related to paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, C3 glomerulopathy, and IgA nephropathy .

HY-P992456

SAR-443809	Complement System	Cardiovascular Disease Endocrinology
SAR-443809 is a selective alternative complement system inhibitor and monoclonal antibody targeting complement factor Bb. SAR-443809 blocks the cleavage of C3 and factor B by selectively binding to the activated form of factor Bb, with a K_D of 7.3 nM for human factor Bb. SAR-443809 inhibits the amplification loop of the alternative complement pathway and C3 activation, reduces C3b deposition, and blocks the activation of pathways associated with intravascular and extravascular hemolysis. SAR-443809 can be used for the research of hematological and renal disorders mediated by abnormal alternative complement pathway .

HY-114214

CKD-712	Drug Derivative NF-κB MMP TNF Receptor Interleukin Related Cyclin G-associated Kinase (GAK) CDK PI3K Akt	Inflammation/Immunology Cancer
CKD-712 is an orally active multi-target tetrahydroisoquinoline derivatived and a potent inhibitor of the NF-κB pathway . CKD-712 selectively inhibits MMP-9 with no effect on MMP-2, downregulates the expression of TNF-α, IL-6, cyclin A, cyclin B, CDK-1 and other proteins, and activates the PI3K/Akt signaling pathway . CKD-712 blocks the activation and nuclear translocation of NF-κB, downregulates inflammatory factors and pro-tumor metastatic proteins, and induces G2/M phase arrest in tumor cells and thereby inhibits the invasion of cancer cells . CKD-712 can be used for the research of sepsis, myocardial ischemia-reperfusion injury and non-small cell lung cancer .

Cat. No.	Product Name

HY-L145

Antihypertensive Compound Library	893 compounds
The majority of hypertensive patients have primary (or essential) hypertension, that is, hypertension in which secondary causes are not present. Management aims to control arterial pressure, prevent end-organ damage (cerebrovascular, cardiovascular, and renal), and reduce the risk of premature death. Antihypertensive drugs may be divided into two broad groups, the first group being those which directly or indirectly block the renin–angiotensin system (RAS), for example, ACEIs, angiotensin receptor antagonists (ARAs), direct renin inhibitors (DRIs), and to a lesser extent β-blockers. The second group of drugs works by increasing water and sodium excretion, thereby reducing intravascular volume, or by causing vasodilatation through non-RAS pathways, for example, diuretics and calcium channel blockers (CCBs). MCE offers a unique collection of 893 compounds with identified and potential antihypertensive activity. MCE Antihypertensive Compound Library is critical for antihypertensive drug discovery and development.

Antihypertensive Compound Library

893 compounds

The majority of hypertensive patients have primary (or essential) hypertension, that is, hypertension in which secondary causes are not present. Management aims to control arterial pressure, prevent end-organ damage (cerebrovascular, cardiovascular, and renal), and reduce the risk of premature death.

Antihypertensive drugs may be divided into two broad groups, the first group being those which directly or indirectly block the renin–angiotensin system (RAS), for example, ACEIs, angiotensin receptor antagonists (ARAs), direct renin inhibitors (DRIs), and to a lesser extent β-blockers. The second group of drugs works by increasing water and sodium excretion, thereby reducing intravascular volume, or by causing vasodilatation through non-RAS pathways, for example, diuretics and calcium channel blockers (CCBs).

MCE offers a unique collection of 893 compounds with identified and potential antihypertensive activity. MCE Antihypertensive Compound Library is critical for antihypertensive drug discovery and development.

Hydroxyethyl starch (MW170-230 kDa)	Biochemical Assay Reagents
Hydroxyethyl starch (MW170-230 kDa) is a type of hydroxyethyl starch with a molecular weight of 170-230 kDa. A medium-molecular-weight hydroxyethyl starch (HES 200/0.62) exhibits minimal intravascular hydrolysis. The rapidly degradable medium-molecular-weight Hydroxyethyl starch 200/0.5 causes almost no coagulation disorders and improves hemorheological parameters .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990952

Zaltenibart OMS906	Ser/Thr Protease Complement System	Metabolic Disease Inflammation/Immunology
Zaltenibart (OMS906) is an IgG4 humanized monoclonal antibody and MASP-3 inhibitor. By inhibiting MASP-3, Zaltenibart achieves upstream inhibition of the alternative complement pathway. MASP-3 is an upstream activator of Factor D (Factor D), a key enzyme in the alternative complement pathway. Zaltenibart prevents both intravascular hemolysis and extravascular hemolysis. Zaltenibart is applicable to research related to paroxysmal nocturnal hemoglobinuria .

HY-P991022

Ruxoprubart NM8074	Complement System	Endocrinology
Ruxoprubart (NM8074) is an inhibitor of complement factor B (Bb subunit). Ruxoprubart selectively binds to active Bb to inhibit the alternative complement pathway without affecting the classical complement pathway. By blocking the activities of AP C3 and C5 convertases, Ruxoprubart effectively inhibits red blood cell hemolysis and reduces C3b deposition, thereby preventing intravascular and extravascular hemolysis. Ruxoprubart can be used in research related to paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, C3 glomerulopathy, and IgA nephropathy .

HY-P992456

SAR-443809	Complement System	Cardiovascular Disease Endocrinology
SAR-443809 is a selective alternative complement system inhibitor and monoclonal antibody targeting complement factor Bb. SAR-443809 blocks the cleavage of C3 and factor B by selectively binding to the activated form of factor Bb, with a K_D of 7.3 nM for human factor Bb. SAR-443809 inhibits the amplification loop of the alternative complement pathway and C3 activation, reduces C3b deposition, and blocks the activation of pathways associated with intravascular and extravascular hemolysis. SAR-443809 can be used for the research of hematological and renal disorders mediated by abnormal alternative complement pathway .

Iopromide-d3
Iopromide-d₃ is the deuterium labeled Iopromide. Iopromide is a non-ionic, monomeric, iodine-based contrast medium for intravascular administration.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: